RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01149356
First received: June 22, 2010
Last updated: September 23, 2013
Last verified: September 2013

June 22, 2010
September 23, 2013
October 2010
April 2013   (final data collection date for primary outcome measure)
  • Incidence of treatment emergent adverse events (TEAEs) based on CTCAE version 3 grade (Phase I) [ Time Frame: Up to 70 days ] [ Designated as safety issue: Yes ]
    Will be summarized by body system, preferred term, verbatim of adverse event, intensity, and relationship to each study drug (BMS-936558 and/or the peptide vaccine).
  • Time to relapse (Phase II) [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
    Time to relapse will be summarized using descriptive statistics.
  • Progression-free survival (phase II) [ Designated as safety issue: No ]
  • Maximum-tolerated dose or the recommended phase II dose of gamma-secretase inhibitor RO4929097 (phase I) [ Designated as safety issue: Yes ]
  • Safety and tolerability of gamma-secretase inhibitor RO4929097 (phase I) [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01149356 on ClinicalTrials.gov Archive Site
Overall survival (Phase II) [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
  • Overall survival (phase II) [ Designated as safety issue: No ]
  • Adverse events (phase II) [ Designated as safety issue: Yes ]
  • Objective response (phase II) [ Designated as safety issue: No ]
Not Provided
Not Provided
 
RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer
A Phase I Dose Escalation Trial of RO4929097 Administered in Combination With Exemestane in Pre- and Postmenopausal Patients With ER + Metastatic Breast Cancer / A Randomized Phase II Trial Comparing Exemestane in Combination With RO4929097 Compared With Exemestane Alone as Second or Third Line Hormonal Treatment of ER + Metastatic Breast Cancer in Pre- and Post-Menopausal Patients

This partially randomized phase I/II trial is studying the side effects and the best dose of RO4929097 when given together with exemestane and to see how well it works compared to exemestane alone in treating premenopausal and postmenopausal patients with advanced or metastatic breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by lowering the amount of estrogen the body makes. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving exemestane together with RO4929097 may kill more breast cancer cells.

PRIMARY OBJECTIVES:

I. Determine the maximum-tolerated dose or the recommended phase II dose of gamma-secretase inhibitor RO4929097 (RO4929097) in combination with exemestane in pre- and postmenopausal patients with estrogen receptor-positive (ER+) advanced or metastatic breast cancer.

II. Determine the safety and tolerability of this regimen in these patients. III. Determine the progression-free survival of patients treated with exemestane with vs without RO4929097.

SECONDARY OBJECTIVES:

I. Determine the overall tumor response rate in patients treated with these regimens.

II. Determine the overall survival of patients treated with these regimens. III. Determine the safety of these regimens in these patients. IV. Determine the quality of life of patients treated with these regimens. V. Identify biomarkers of response to treatment or toxicity.

OUTLINE: This is a multicenter, phase I, dose-escalation study of gamma-secretase inhibitor RO4929097 followed by a randomized phase II study.

PHASE I:

Patients receive oral exemestane once daily on days 1-21 and oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

PHASE II: Patients are stratified according to menopausal status (pre- vs postmenopausal) and visceral disease (yes vs no). Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive exemestane as in phase I and oral gamma-secretase inhibitor RO4929097 at the MTD determined in phase I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive exemestane as in arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

In addition to exemestane, pre-menopausal patients receive goserelin subcutaneously every 28 days. Patients may undergo blood and tissue sample collection for correlative studies.

Patients may complete quality-of-life questionnaires at baseline and periodically during study using the Functional Assessment of Cancer Therapy for Breast Cancer (FACT-B).

After completion of study therapy, patients are followed up for 4 weeks and then every 6 months thereafter.

Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Estrogen Receptor-positive Breast Cancer
  • HER2-negative Breast Cancer
  • Male Breast Cancer
  • Recurrent Breast Cancer
  • Stage IIIB Breast Cancer
  • Stage IIIC Breast Cancer
  • Stage IV Breast Cancer
  • Drug: exemestane
    Given orally
    Other Names:
    • Aromasin
    • FCE-24304
    • PNU 155971
  • Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
    Given orally
    Other Names:
    • R4733
    • RO4929097
  • Drug: goserelin acetate
    Given subcutaneously to premenopausal patients
    Other Names:
    • ICI-118630
    • ZDX
    • Zoladex
  • Experimental: Arm I
    Patients receive oral exemestane once daily on days 1-21 and oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
    Interventions:
    • Drug: exemestane
    • Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
    • Drug: goserelin acetate
  • Active Comparator: Arm II
    Patients receive exemestane as in arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
    Interventions:
    • Drug: exemestane
    • Drug: goserelin acetate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
30
Not Provided
April 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of breast cancer

    • Locally advanced or metastatic disease for which curative measures are not effective

      • Relapsed disease with (or within 6 months of discontinuation of) an adjuvant nonsteroidal aromatase inhibitor or tamoxifen
      • Progressive disease during treatment with first- or second-line hormonal therapy that could include a nonsteroidal aromatase inhibitor, tamoxifen, or fulvestrant
    • Recurrent disease

      • No locally recurrent resectable disease
    • Histologically confirmed estrogen receptor-positive (ER+) by IHC

      • Must have ≥ 5% strong staining for ER+ or ≥ 10% weak staining
  • Measurable disease defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 20 mm by conventional techniques OR as ≥ 10 mm by spiral CT scan
  • No HER2/neu-positive disease
  • No known brain metastases
  • Pre- or postmenopausal status
  • ECOG performance status 0-1
  • Life expectancy ≥ 6 months
  • WBC ≥ 3,500/mm^3
  • ANC ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 9 g/dL
  • Total bilirubin ≤ 2 mg/dL
  • AST and ALT ≤ 2.5 times upper limit of normal
  • Creatinine normal OR creatinine clearance ≥ 60 mL/min
  • Able to swallow and retain oral medication
  • Negative pregnancy test
  • Not pregnant or nursing
  • Fertile patients must use effective contraception during and for ≥ 12 months after completion of study therapy
  • More than 5 years since other invasive cancer except basal or squamous cell cancer of the skin or cervical carcinoma in situ
  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to gamma-secretase inhibitor RO4929097 or other agents used in the study
  • No history of torsades de pointes
  • No malabsorption syndrome or other condition that would interfere with intestinal absorption (e.g., ulcerative colitis)
  • Not serologically positive for hepatitis B or C, have a history of liver disease, other forms of hepatitis, or cirrhosis
  • No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, or hypokalemia
  • No uncontrolled intercurrent illness including, but not limited to, any of the following:

    • Ongoing or active infection requiring parenteral antibiotics
    • Impairment of lung function (e.g., chronic obstructive pulmonary disease or lung conditions requiring oxygen therapy)
    • Symptomatic congestive heart failure (NYHA class III-IV heart disease)
    • Unstable angina pectoris, angioplasty, stenting, and or myocardial infarction within the past 6 months
    • Uncontrolled hypertension (systolic BP > 180 mm Hg or diastolic BP > 100 mm Hg on 2 consecutive measurements separated by a 1-week period) despite adequate medical support
    • Clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, torsades de pointes, ventricular tachycardia that is symptomatic, or requiring treatment)
    • A requirement for antiarrthymics or other medications known to prolong QTC
    • Uncontrolled diabetes (hyperosmolar state, ketoacidosis, etc.)
    • Psychiatric illness and/or social situations that would limit compliance with study requirements
  • No baseline QTcF > 450 msec (male) or > 470 msec (female)
  • See Disease Characteristics
  • Fully recovered from all previous adverse events
  • No prior exemestane for metastatic or recurrent breast cancer, or within the past 6 months in the adjuvant setting
  • More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
  • At least 2 weeks since prior radiotherapy
  • At least 2 weeks since prior and no other concurrent investigational agents
  • No prior exposure to γ-secretase inhibitors
  • No concurrent medications with narrow therapeutic indices that are metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin®)
  • No other concurrent CYP3A4 substrates, inducers, or inhibitors
  • No concurrent combination antiretroviral therapy for HIV-positive patients
  • No other concurrent anticancer agents or therapies, including chemotherapy, radiotherapy, surgery, immunotherapy, hormonal therapy, or biologic therapy
  • No concurrent medications or food that may interfere with the metabolism of gamma-secretase inhibitor RO4929097, including ketoconazole and grapefruit juice
  • No concurrent antiarrhythmics or other medications known to prolong QTc
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01149356
NCI-2010-02181, NCI-2010-02181, MCC-8539, CDR0000675612, 8539, 8539, N01CM00100
Not Provided
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Julie Means-Powell H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP